Adaptimmune pockets GSK payouts after tripling size of TCR trial

Nick Paul Taylor

has bagged two milestones from GlaxoSmithKline. The checks landed in 's bank account it tripled the of a Phase I/II synovial sarcoma of its NY-ESO-1-targeting T-cell receptor (TCR) therapy on the strength of data from the initial cohort.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS